<p> Further to the request from the Combinations Alliance for clarity on which drugs and areas of scientific interest are open for collaboration under the master terms of agreement, AstraZeneca/MedImmune are pleased to provide this detail as follows.</p><p>Any proposals that are of interest and that AZ/MedImmune and our Alliance partners would be keen to progress, will be reviewed by AZ/MedImmune internal governance in order to secure appropriate funding prior to a decision</p><p>AZD1775 (Wee1 inhibitor) Project representative: [email protected] . Development stage - Phase II . Settings of interest :- . Monotherapy o Beyond ovarian, TNBC and SCLC- such as HER2+ breast cancer, gastric, lung, hemes</p><p>. Combination with other DDR agents- including sequencing of drugs o Olaparib- Beyond ovarian, TNBC, SCLC such as prostate, pancreas, gastric, HNSCC o ATR o ATM o Other novel checkpoint agents</p><p>. Combination with Immunotherapy o Beyond ovarian, TNBC, SCLC such as HNSCC, NSCLC, gastric, pancreas, bladder, HCC, and Hemes (MM, FL, AML, DLBCL)</p><p>. Combination with Chemotherapy o Chemotherapy including novel chemotherapy and formulation developed chemotherapy- Including ovarian, TNBC, SCLC o Radiation o Novel/Novel Combinations- VEGF, mTor, AKT, etc</p><p>. Other study designs o Neo-adjuvant o Radiation o Novel/Novel Combinations- VEGF, mTor, AKT, etc o Window studies o Maintenance o Sequencing studies o Basket approaches in DDR and others o Peadiatrics o Other special patient populations</p><p>. Please contact the project representative to discuss prioritized clinical settings for external collaboration. Collaborators may need to generate additional preclinical work to support clinical settings of interest.</p><p>AZD9150 (STAT3 Antisense oligonucleotide) Project representative: [email protected] .Development stage - Phase II . Settings of interest - o Combination studies exploiting the emerging immunomodulatory role of AZD9150 o Correlative studies to understand better the immunomodulatory role of AZD9150 . Please contact the project representative to discuss prioritized clinical settings for external collaboration. Collaborators may need to generate additional preclinical work to support clinical settings of interest. </p><p>AZD5069 (CXCR2 inhibitor) Project representative: [email protected] .Development stage - Phase II . Settings of interest - o Combination studies exploiting the emerging role of CXCR2 and immunomodulatory role of AZD5069 o Correlative studies to understand better the immunomodulatory role of AZD5069 . Please contact the project representative to discuss prioritized clinical settings for external collaboration. Collaborators may need to generate additional preclinical work to support clinical settings of interest. </p><p>AZD9496 (Selective oestrogen receptor downregulator) Project representative: [email protected] 1 .Development stage - Phase I  Settings of interest - In combinations with other novel targeted biological agents and other endocrine therapies – e.g. AI; Subgroups with ER+ Mutations</p><p> Monotherapy (e.g. 1st line endocrine naïve or receiving adjuvant endocrine therapy and later lines of therapy. As maintenance therapy after tumour stabilisation by chemotherapy)  Monotherapy and Combinations in Pre- and peri-menopausal women</p><p> ER+ endometrial or ovarian cancer may also be considered</p><p>. Please contact the project representative to discuss prioritized clinical settings for external collaboration. Collaborators may need to generate additional preclinical work to support clinical settings of interest.</p><p>Tagrisso [AZD9291] (EGFRm NSCLC). Project representative: [email protected]</p><p>. Development stage - Phase III & post launch </p><p> Settings of interest:</p><p> Second –lines and beyond o Disease management pathways o Characterization of ILD o Explore dose scheduling options o Local/regional practice variations o Measurement of unmet need o Adverse event management</p><p> Diagnostic Testing</p><p> First –Line Therapy o Primary resistance 1L o Uncommon EGFR mutations o Oligometastatic disease + SRS o Other resistance to 1L EGFR TKIs o Paired tumor/non-tumor resistance o Treatment beyond progression</p><p> Combinations o Targeted small molecules o Combination immunotherapies – current and novel o Vaccines o Combination VEGFR inhibitors o Sequencing studies</p><p> Earlier stages of NSCLC disease</p><p> Special Populations o Patients with CNS & LM disease o Primary or acquired resistance ≥ 2L o Elderly o Poor performance status o Germline T790M resistance o Other tumor types</p><p>2</p>